1
|
Moran MW, Ramirez EP, Zook JD, Saarinen AM, Baravati B, Goode MR, Laloudakis V, Kaschner EK, Olson TL, Craciunescu FM, Hansen DT, Liu J, Fromme P. Biophysical characterization and a roadmap towards the NMR solution structure of G0S2, a key enzyme in non-alcoholic fatty liver disease. PLoS One 2021; 16:e0249164. [PMID: 34260600 PMCID: PMC8279337 DOI: 10.1371/journal.pone.0249164] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2020] [Accepted: 03/13/2021] [Indexed: 11/19/2022] Open
Abstract
In the United States non-alcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease, affecting an estimated 80 to 100 million people. It occurs in every age group, but predominantly in people with risk factors such as obesity and type 2 diabetes. NAFLD is marked by fat accumulation in the liver leading to liver inflammation, which may lead to scarring and irreversible damage progressing to cirrhosis and liver failure. In animal models, genetic ablation of the protein G0S2 leads to alleviation of liver damage and insulin resistance in high fat diets. The research presented in this paper aims to aid in rational based drug design for the treatment of NAFLD by providing a pathway for a solution state NMR structure of G0S2. Here we describe the expression of G0S2 in an E. coli system from two different constructs, both of which are confirmed to be functionally active based on the ability to inhibit the activity of Adipose Triglyceride Lipase. In one of the constructs, preliminary NMR spectroscopy measurements show dominant alpha-helical characteristics as well as resonance assignments on the N-terminus of G0S2, allowing for further NMR work with this protein. Additionally, the characterization of G0S2 oligomers are outlined for both constructs, suggesting that G0S2 may defensively exist in a multimeric state to protect and potentially stabilize the small 104 amino acid protein within the cell. This information presented on the structure of G0S2 will further guide future development in the therapy for NAFLD.
Collapse
Affiliation(s)
- Michael W. Moran
- Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ, United States of America
- School of Molecular Sciences, Arizona State University, Tempe, AZ, United States of America
| | - Elizabeth P. Ramirez
- Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ, United States of America
- School of Molecular Sciences, Arizona State University, Tempe, AZ, United States of America
| | - James D. Zook
- Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ, United States of America
| | - Alicia M. Saarinen
- Department of Biochemistry and Molecular Biology, Mayo Clinic in Arizona Scottsdale, AZ, United States of America
- Department of Cardiovascular Medicine, Mayo Clinic in Arizona Scottsdale, AZ, United States of America
| | - Bobby Baravati
- Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ, United States of America
- School of Molecular Sciences, Arizona State University, Tempe, AZ, United States of America
| | - Matthew R. Goode
- Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ, United States of America
- School of Molecular Sciences, Arizona State University, Tempe, AZ, United States of America
| | - Vasiliki Laloudakis
- Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ, United States of America
| | - Emily K. Kaschner
- Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ, United States of America
- School of Molecular Sciences, Arizona State University, Tempe, AZ, United States of America
| | - Tien L. Olson
- Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ, United States of America
- School of Molecular Sciences, Arizona State University, Tempe, AZ, United States of America
| | - Felicia M. Craciunescu
- Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ, United States of America
| | - Debra T. Hansen
- Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ, United States of America
- Biodesign Center for Innovations in Medicine, Arizona State University, Tempe, AZ, United States of America
| | - Jun Liu
- Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, United States of America
| | - Petra Fromme
- Biodesign Center for Applied Structural Discovery, Arizona State University, Tempe, AZ, United States of America
- School of Molecular Sciences, Arizona State University, Tempe, AZ, United States of America
- * E-mail:
| |
Collapse
|
2
|
Yaron JR, Zhang L, Guo Q, Awo EA, Burgin M, Schutz LN, Zhang N, Kilbourne J, Daggett-Vondras J, Lowe KM, Lucas AR. Recombinant Myxoma Virus-Derived Immune Modulator M-T7 Accelerates Cutaneous Wound Healing and Improves Tissue Remodeling. Pharmaceutics 2020; 12:E1003. [PMID: 33105865 PMCID: PMC7690590 DOI: 10.3390/pharmaceutics12111003] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Revised: 10/16/2020] [Accepted: 10/21/2020] [Indexed: 12/26/2022] Open
Abstract
Complex dermal wounds represent major medical and financial burdens, especially in the context of comorbidities such as diabetes, infection and advanced age. New approaches to accelerate and improve, or "fine tune" the healing process, so as to improve the quality of cutaneous wound healing and management, are the focus of intense investigation. Here, we investigate the topical application of a recombinant immune modulating protein which inhibits the interactions of chemokines with glycosaminoglycans, reducing damaging or excess inflammation responses in a splinted full-thickness excisional wound model in mice. M-T7 is a 37 kDa-secreted, virus-derived glycoprotein that has demonstrated therapeutic efficacy in numerous animal models of inflammatory immunopathology. Topical treatment with recombinant M-T7 significantly accelerated wound healing when compared to saline treatment alone. Healed wounds exhibited properties of improved tissue remodeling, as determined by collagen maturation. M-T7 treatment accelerated the rate of peri-wound angiogenesis in the healing wounds with increased levels of TNF, VEGF and CD31. The immune cell response after M-T7 treatment was associated with a retention of CCL2 levels, and increased abundances of arginase-1-expressing M2 macrophages and CD4 T cells. Thus, topical treatment with recombinant M-T7 promotes a pro-resolution environment in healing wounds, and has potential as a novel treatment approach for cutaneous tissue repair.
Collapse
Affiliation(s)
- Jordan R. Yaron
- Center for Personalized Diagnostics and Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA; (J.R.Y.); (Q.G.); (E.A.A.); (M.B.); (L.N.S.); (N.Z.)
| | - Liqiang Zhang
- Center for Personalized Diagnostics and Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA; (J.R.Y.); (Q.G.); (E.A.A.); (M.B.); (L.N.S.); (N.Z.)
| | - Qiuyun Guo
- Center for Personalized Diagnostics and Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA; (J.R.Y.); (Q.G.); (E.A.A.); (M.B.); (L.N.S.); (N.Z.)
| | - Enkidia A. Awo
- Center for Personalized Diagnostics and Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA; (J.R.Y.); (Q.G.); (E.A.A.); (M.B.); (L.N.S.); (N.Z.)
| | - Michelle Burgin
- Center for Personalized Diagnostics and Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA; (J.R.Y.); (Q.G.); (E.A.A.); (M.B.); (L.N.S.); (N.Z.)
| | - Lauren N. Schutz
- Center for Personalized Diagnostics and Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA; (J.R.Y.); (Q.G.); (E.A.A.); (M.B.); (L.N.S.); (N.Z.)
| | - Nathan Zhang
- Center for Personalized Diagnostics and Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA; (J.R.Y.); (Q.G.); (E.A.A.); (M.B.); (L.N.S.); (N.Z.)
| | - Jacquelyn Kilbourne
- Department of Animal Care and Technologies, Arizona State University, Tempe, AZ 85287, USA; (J.K.); (J.D.-V.); (K.M.L.)
| | - Juliane Daggett-Vondras
- Department of Animal Care and Technologies, Arizona State University, Tempe, AZ 85287, USA; (J.K.); (J.D.-V.); (K.M.L.)
| | - Kenneth M. Lowe
- Department of Animal Care and Technologies, Arizona State University, Tempe, AZ 85287, USA; (J.K.); (J.D.-V.); (K.M.L.)
| | - Alexandra R. Lucas
- Center for Personalized Diagnostics and Center for Immunotherapy, Vaccines and Virotherapy, The Biodesign Institute, Arizona State University, Tempe, AZ 85287, USA; (J.R.Y.); (Q.G.); (E.A.A.); (M.B.); (L.N.S.); (N.Z.)
| |
Collapse
|